Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Vaccine. 2010 Oct 21;28(45):7273-8. doi: 10.1016/j.vaccine.2010.08.085. Epub 2010 Sep 9.

Candidate hepatitis C vaccine trials and people who inject drugs: challenges and opportunities.

Author information

  • 1National Centre in HIV Epidemiology and Clinical Research, School of Public Health and Community Medicine, University of New South Wales, Centre for Immunology, Darlinghurst, NSW 2010, Australia. LMaher@nchecr.unsw.edu.au

Abstract

People who inject drugs (PWID) are at high risk of HCV. Limited evidence of the effectiveness of prevention interventions and low uptake of treatment in this group highlight the need for increased investment in biomedical interventions, notably safe and efficacious vaccines. While several candidates are currently in development, field trials in PWID present challenges, including ethical issues associated with trial literacy, informed consent and standards of care. Significant biological and social factors and differences between HIV and HCV suggest that HCV warrants targeted vaccine preparedness research to lay the groundwork for successful implementation of future trials.

Copyright © 2010 Elsevier Ltd. All rights reserved.

PMID:
20831914
[PubMed - indexed for MEDLINE]
PMCID:
PMC3729933
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Write to the Help Desk